Advertisement

Neuroscience Bulletin

, Volume 32, Issue 4, pp 398–420 | Cite as

The Immune System and the Role of Inflammation in Perinatal Depression

  • Philippe Leff-Gelman
  • Ismael Mancilla-Herrera
  • Mónica Flores-Ramos
  • Carlos Cruz-Fuentes
  • Juan Pablo Reyes-Grajeda
  • María del Pilar García-Cuétara
  • Marielle Danitza Bugnot-Pérez
  • David Ellioth Pulido-Ascencio
Review

Abstract

Major depression during pregnancy is a common psychiatric disorder that arises from a complex and multifactorial etiology. Psychosocial stress, sex, hormones, and genetic vulnerability increase the risk for triggering mood disorders. Microglia and toll-like receptor 4 play a crucial role in triggering wide and varied stress-induced responses mediated through activation of the inflammasome; this leads to the secretion of inflammatory cytokines, increased serotonin metabolism, and reduction of neurotransmitter availability along with hypothalamic–pituitary–adrenal axis hyperactivity. Dysregulation of this intricate neuroimmune communication network during pregnancy modifies the maternal milieu, enhancing the emergence of depressive symptoms and negative obstetric and neuropsychiatric outcomes. Although several studies have clearly demonstrated the role of the innate immune system in major depression, it is still unclear how the placenta, the brain, and the monoaminergic and neuroendocrine systems interact during perinatal depression. Thus, in the present review we describe the cellular and molecular interactions between these systems in major depression during pregnancy, proposing that the same stress-related mechanisms involved in the activation of the NLRP3 inflammasome in microglia and peripheral myeloid cells in depressed patients operate in a similar fashion in the neuroimmune placenta during perinatal depression. Thus, activation of Toll-like receptor 2 and 4 signaling and the NLRP3 inflammasome in placental immune cells may promote a shift of the Th1/Th2 bias towards a predominant Th1/Th17 inflammatory response, associated with increased secretion of pro-inflammatory cytokines, among other secreted autocrine and paracrine mediators, which play a crucial role in triggering and/or exacerbating depressive symptoms during pregnancy.

Keywords

Depression Pregnancy Immune system Inflammation Cytokine Serotonin Indoleamine 2,3 dioxygenase Glucocorticoid Brain Placenta 

Notes

Acknowledgements

This review was supported by the National Institute of Perinatology, Mexico City (234560) and FONSEC SSA/IMSS/ISSSTE 2015-1 (261435).

References

  1. 1.
    Zunszain PA, Anacker C, Cattaneo A, Carvalho LA, Pariante CM. Glucocorticoids, cytokines and brain abnormalities in depression. Prog Neuropsychopharmacol Biol Psychiatry 2010, 35: 722–729.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    Thase ME. Preventing relapse and recurrence of depression: a brief review of therapeutic options. CNS Spectr 2006, 11: 12–21.PubMedCrossRefGoogle Scholar
  3. 3.
    Evans DL, Charney DS, Lewis L, Golden RN, Gorman JM, Krishnan KR, et al. Mood disorders in the medically ill: scientific review and recommendations. Biol Psychiatry 2005, 58: 175–189.PubMedCrossRefGoogle Scholar
  4. 4.
    Galindo-Sevilla N, Leff-Gelman P, Cruz Fuentes C, Cordova Barrios A, Mancilla-Ramirez J, Ramírez-Ramírez A, et al. Immune Function in Pregnant Women with Affective Disorders. Current Psychiatry Reviews 2014, 10: 258–273.CrossRefGoogle Scholar
  5. 5.
    Blackmore ER, Moynihan JA, Rubinow DR, Pressman EK, Gilchrist M, O’Connor TG. Psychiatric symptoms and proinflammatory cytokines in pregnancy. Psychosom Med 2011, 73: 656–663.PubMedPubMedCentralCrossRefGoogle Scholar
  6. 6.
    Cheng CY, Pickler RH. Perinatal stress, fatigue, depressive symptoms, and immune modulation in late pregnancy and one month postpartum. ScientificWorldJournal 2014, 2014: 652630.PubMedPubMedCentralGoogle Scholar
  7. 7.
    Bennett HA, Einarson A, Taddio A, Koren G, Einarson TR. Prevalence of depression during pregnancy: systematic review. Obstet Gynecol 2004, 103: 698–709.PubMedCrossRefGoogle Scholar
  8. 8.
    Marcus SM, Flynn HA, Blow FC, Barry KL. Depressive symptoms among pregnant women screened in obstetrics settings. J Womens Health (Larchmt) 2003, 12: 373–380.CrossRefGoogle Scholar
  9. 9.
    Bittner A, Peukert J, Zimmermann C, Junge-Hoffmeister J, Parker LS, Stobel-Richter Y, et al. Early intervention in pregnant women with elevated anxiety and depressive symptoms: efficacy of a cognitive-behavioral group program. J Perinat Neonatal Nurs 2014, 28: 185–195.PubMedCrossRefGoogle Scholar
  10. 10.
    Stuart-Parrigon K, Stuart S. Perinatal depression: an update and overview. Curr Psychiatry Rep 2014, 16: 468.PubMedPubMedCentralCrossRefGoogle Scholar
  11. 11.
    Milgrom J, Gemmill AW. Screening for perinatal depression. Best Pract Res Clin Obstet Gynaecol 2014, 28: 13–23.PubMedCrossRefGoogle Scholar
  12. 12.
    Zuckerman B, Amaro H, Bauchner H, Cabral H. Depressive symptoms during pregnancy: relationship to poor health behaviors. Am J Obstet Gynecol 1989, 160: 1107–1111.PubMedCrossRefGoogle Scholar
  13. 13.
    Dayan J, Creveuil C, Marks MN, Conroy S, Herlicoviez M, Dreyfus M, et al. Prenatal depression, prenatal anxiety, and spontaneous preterm birth: a prospective cohort study among women with early and regular care. Psychosom Med 2006, 68: 938–946.PubMedCrossRefGoogle Scholar
  14. 14.
    Canady RB, Bullen BL, Holzman C, Broman C, Tian Y. Discrimination and symptoms of depression in pregnancy among African American and White women. Womens Health Issues 2008, 18: 292–300.PubMedPubMedCentralCrossRefGoogle Scholar
  15. 15.
    Cassidy-Bushrow AE, Peters RM, Johnson DA, Templin TN. Association of depressive symptoms with inflammatory biomarkers among pregnant African-American women. J Reprod Immunol 2012, 94: 202–209.PubMedCrossRefGoogle Scholar
  16. 16.
    Orr ST, Blazer DG, James SA. Racial disparities in elevated prenatal depressive symptoms among black and white women in eastern north Carolina. Ann Epidemiol 2006, 16: 463–468.PubMedCrossRefGoogle Scholar
  17. 17.
    Marcus S, Lopez JF, McDonough S, Mackenzie MJ, Flynn H, Neal CR, Jr., et al. Depressive symptoms during pregnancy: impact on neuroendocrine and neonatal outcomes. Infant Behav Dev 2010, 34: 26–34.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Robertson E, Grace S, Wallington T, Stewart DE. Antenatal risk factors for postpartum depression: a synthesis of recent literature. Gen Hosp Psychiatry 2004, 26: 289–295.PubMedCrossRefGoogle Scholar
  19. 19.
    Pakenham KI, Smith A, Rattan SL. Application of a stress and coping model to antenatal depressive symptomatology. Psychol Health Med 2007, 12: 266–277.PubMedCrossRefGoogle Scholar
  20. 20.
    Chien LY, Ko YL. Fatigue during pregnancy predicts caesarean deliveries. J Adv Nurs 2004, 45: 487–494.PubMedCrossRefGoogle Scholar
  21. 21.
    Fairbrother N, Hutton EK, Stoll K, Hall W, Kluka S. Psychometric evaluation of the Multidimensional Assessment of Fatigue scale for use with pregnant and postpartum women. Psychol Assess 2008, 20: 150–158.PubMedCrossRefGoogle Scholar
  22. 22.
    Field T, Diego M, Hernandez-Reif M. Prenatal depression effects on the fetus and newborn: a review. Infant Behav Dev 2006, 29: 445–455.PubMedCrossRefGoogle Scholar
  23. 23.
    Veenstra van Nieuwenhoven AL, Heineman MJ, Faas MM. The immunology of successful pregnancy. Hum Reprod Update 2003, 9: 347–357.PubMedCrossRefGoogle Scholar
  24. 24.
    Nemeroff CB. The corticotropin-releasing factor (CRF) hypothesis of depression: new findings and new directions. Mol Psychiatry 1996, 1: 336–342.PubMedGoogle Scholar
  25. 25.
    Choi AJ, Ryter SW. Inflammasomes: molecular regulation and implications for metabolic and cognitive diseases. Molecules and cells 2014, 37: 441–448.PubMedPubMedCentralCrossRefGoogle Scholar
  26. 26.
    Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain, behavior, and immunity 2013, 31: 105–114.PubMedCrossRefGoogle Scholar
  27. 27.
    Lichtblau N, Schmidt FM, Schumann R, Kirkby KC, Himmerich H. Cytokines as biomarkers in depressive disorder: current standing and prospects. International review of psychiatry 2013, 25: 592–603.PubMedCrossRefGoogle Scholar
  28. 28.
    Anisman H, Hayley S. Inflammatory factors contribute to depression and its comorbid conditions. Science signaling 2012, 5: pe45.Google Scholar
  29. 29.
    Gazal M, Souza LD, Fucolo BA, Wiener CD, Silva RA, Pinheiro RT, et al. The impact of cognitive behavioral therapy on IL-6 levels in unmedicated women experiencing the first episode of depression: a pilot study. Psychiatry Res 2013, 209: 742–745.PubMedCrossRefGoogle Scholar
  30. 30.
    McGuinness TM, Dyer JG, Wade EH. Gender differences in adolescent depression. Journal of psychosocial nursing and mental health services 2012, 50: 17–20.PubMedGoogle Scholar
  31. 31.
    Dahl RE, Gunnar MR. Heightened stress responsiveness and emotional reactivity during pubertal maturation: implications for psychopathology. Development and psychopathology 2009, 21: 1–6.PubMedCrossRefGoogle Scholar
  32. 32.
    Cyranowski JM, Frank E, Young E, Shear MK. Adolescent onset of the gender difference in lifetime rates of major depression: a theoretical model. Archives of general psychiatry 2000, 57: 21–27.PubMedCrossRefGoogle Scholar
  33. 33.
    Patton GC, Viner R. Pubertal transitions in health. Lancet 2007, 369: 1130–1139.PubMedCrossRefGoogle Scholar
  34. 34.
    Kessler RC, Demler O, Frank RG, Olfson M, Pincus HA, Walters EE, et al. Prevalence and treatment of mental disorders, 1990 to 2003. The New England journal of medicine 2005, 352: 2515–2523.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Eaton NR, Keyes KM, Krueger RF, Balsis S, Skodol AE, Markon KE, et al. An invariant dimensional liability model of gender differences in mental disorder prevalence: evidence from a national sample. Journal of abnormal psychology 2012, 121: 282–288.PubMedCrossRefGoogle Scholar
  36. 36.
    Holder MK, Blaustein JD. Puberty and adolescence as a time of vulnerability to stressors that alter neurobehavioral processes. Front Neuroendocrinol 2014, 35: 89–110.PubMedCrossRefGoogle Scholar
  37. 37.
    Hayward C, Sanborn K. Puberty and the emergence of gender differences in psychopathology. The Journal of adolescent health: official publication of the Society for Adolescent Medicine 2002, 30: 49–58.CrossRefGoogle Scholar
  38. 38.
    Scott JP, Stewart JM, De Ghett VJ. Critical periods in the organization of systems. Developmental psychobiology 1974, 7: 489–513.PubMedCrossRefGoogle Scholar
  39. 39.
    Lenz KM, Nugent BM, McCarthy MM. Sexual differentiation of the rodent brain: dogma and beyond. Frontiers in neuroscience 2012, 6: 26.PubMedPubMedCentralCrossRefGoogle Scholar
  40. 40.
    McCarthy MM. How it’s made: organisational effects of hormones on the developing brain. J Neuroendocrinol 2010, 22: 736–742.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Sisk CL, Zehr JL. Pubertal hormones organize the adolescent brain and behavior. Front Neuroendocrinol 2005, 26: 163–174.PubMedCrossRefGoogle Scholar
  42. 42.
    Roberti J. A review of behavioral and biological correlates of sensation seeking. Journal of Research in Personality 2004, 38: 256–279.CrossRefGoogle Scholar
  43. 43.
    Im-Bolter N, Cohen NJ, Farnia F. I thought we were good: social cognition, figurative language, and adolescent psychopathology. Journal of child psychology and psychiatry, and allied disciplines 2013, 54: 724–732.PubMedCrossRefGoogle Scholar
  44. 44.
    MacPherson L, Magidson JF, Reynolds EK, Kahler CW, Lejuez CW. Changes in sensation seeking and risk-taking propensity predict increases in alcohol use among early adolescents. Alcoholism, clinical and experimental research 2010, 34: 1400–1408.PubMedPubMedCentralGoogle Scholar
  45. 45.
    Nimmerjahn A, Kirchhoff F, Helmchen F. Resting microglial cells are highly dynamic surveillants of brain parenchyma in vivo. Science 2005, 308: 1314–1318.PubMedCrossRefGoogle Scholar
  46. 46.
    Tremblay ME, Stevens B, Sierra A, Wake H, Bessis A, Nimmerjahn A. The role of microglia in the healthy brain. The Journal of neuroscience: the official journal of the Society for Neuroscience 2011, 31: 16064–16069.CrossRefGoogle Scholar
  47. 47.
    Wake H, Moorhouse AJ, Jinno S, Kohsaka S, Nabekura J. Resting microglia directly monitor the functional state of synapses in vivo and determine the fate of ischemic terminals. The Journal of neuroscience: the official journal of the Society for Neuroscience 2009, 29: 3974–3980.CrossRefGoogle Scholar
  48. 48.
    Verney C, Monier A, Fallet-Bianco C, Gressens P. Early microglial colonization of the human forebrain and possible involvement in periventricular white-matter injury of preterm infants. J Anat 2011, 217: 436–448.CrossRefGoogle Scholar
  49. 49.
    Mohr MA, Sisk CL. Pubertally born neurons and glia are functionally integrated into limbic and hypothalamic circuits of the male Syrian hamster. Proc Natl Acad Sci U S A 2013, 110: 4792–4797.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Gomez-Gonzalez B, Escobar A. Prenatal stress alters microglial development and distribution in postnatal rat brain. Acta Neuropathol 2010, 119: 303–315.PubMedCrossRefGoogle Scholar
  51. 51.
    Perry VH, Newman TA, Cunningham C. The impact of systemic infection on the progression of neurodegenerative disease. Nat Rev Neurosci 2003, 4: 103–112.PubMedCrossRefGoogle Scholar
  52. 52.
    Kettenmann H, Hanisch UK, Noda M, Verkhratsky A. Physiology of microglia. Physiological reviews 2011, 91: 461–553.PubMedCrossRefGoogle Scholar
  53. 53.
    Streit WJ. Microglial activation and neuroinflammation in Alzheimer’s disease: a critical examination of recent history. Frontiers in aging neuroscience 2010, 2: 22.PubMedPubMedCentralGoogle Scholar
  54. 54.
    Felger JC, Lotrich FE. Inflammatory cytokines in depression: neurobiological mechanisms and therapeutic implications. Neuroscience 2013, 246: 199–229.PubMedPubMedCentralCrossRefGoogle Scholar
  55. 55.
    Yirmiya R, Goshen I. Immune modulation of learning, memory, neural plasticity and neurogenesis. Brain Behav Immun 2010, 25: 181–213.PubMedCrossRefGoogle Scholar
  56. 56.
    Capuron L, Miller AH. Immune system to brain signaling: neuropsychopharmacological implications. Pharmacol Ther 2011, 130: 226–238.PubMedPubMedCentralCrossRefGoogle Scholar
  57. 57.
    Jones KA, Thomsen C. The role of the innate immune system in psychiatric disorders. Molecular and cellular neurosciences 2013, 53: 52–62.PubMedCrossRefGoogle Scholar
  58. 58.
    Hou R, Baldwin DS. A neuroimmunological perspective on anxiety disorders. Human psychopharmacology 2012, 27: 6–14.PubMedCrossRefGoogle Scholar
  59. 59.
    Bilbo SD, Schwarz JM. Early-life programming of later-life brain and behavior: a critical role for the immune system. Frontiers in behavioral neuroscience 2009, 3: 14.PubMedPubMedCentralCrossRefGoogle Scholar
  60. 60.
    Danese A, Moffitt TE, Harrington H, Milne BJ, Polanczyk G, Pariante CM, et al. Adverse childhood experiences and adult risk factors for age-related disease: depression, inflammation, and clustering of metabolic risk markers. Archives of pediatrics & adolescent medicine 2009, 163: 1135–1143.CrossRefGoogle Scholar
  61. 61.
    Danese A, Pariante CM, Caspi A, Taylor A, Poulton R. Childhood maltreatment predicts adult inflammation in a life-course study. Proc Natl Acad Sci U S A 2007, 104: 1319–1324.PubMedPubMedCentralCrossRefGoogle Scholar
  62. 62.
    Salim S, Chugh G, Asghar M. Inflammation in anxiety. Advances in protein chemistry and structural biology 2012, 88: 1–25.PubMedCrossRefGoogle Scholar
  63. 63.
    Bilbo SD, Smith SH, Schwarz JM. A lifespan approach to neuroinflammatory and cognitive disorders: a critical role for glia. Journal of neuroimmune pharmacology: the official journal of the Society on NeuroImmune Pharmacology 2012, 7: 24–41.CrossRefGoogle Scholar
  64. 64.
    Miller AH, Maletic V, Raison CL. Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry 2009, 65: 732–741.PubMedPubMedCentralCrossRefGoogle Scholar
  65. 65.
    Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nature reviews. Immunology 2015, 16: 22–34.CrossRefGoogle Scholar
  66. 66.
    Al-Daghri NM, Al-Ajlan AS, Alfawaz H, Yakout SM, Aljohani N, Kumar S, et al. Serum cytokine, chemokine and hormone levels in Saudi adults with pre-diabetes: a one-year prospective study. Int J Clin Exp Pathol 2015, 8: 11587–11593.PubMedPubMedCentralGoogle Scholar
  67. 67.
    Maes M. Major depression and activation of the inflammatory response system. Adv Exp Med Biol 1999, 461: 25–46.PubMedCrossRefGoogle Scholar
  68. 68.
    Drago A, Crisafulli C, Calabro M, Serretti A. Enrichment pathway analysis. The inflammatory genetic background in Bipolar Disorder. Journal of affective disorders 2015, 179: 88–94.PubMedCrossRefGoogle Scholar
  69. 69.
    Mostafavi S, Battle A, Zhu X, Potash JB, Weissman MM, Shi J, et al. Type I interferon signaling genes in recurrent major depression: increased expression detected by whole-blood RNA sequencing. Molecular psychiatry 2014, 19: 1267–1274.PubMedCrossRefGoogle Scholar
  70. 70.
    Bufalino C, Hepgul N, Aguglia E, Pariante CM. The role of immune genes in the association between depression and inflammation: a review of recent clinical studies. Brain, behavior, and immunity 2013, 31: 31–47.PubMedCrossRefGoogle Scholar
  71. 71.
    Raison CL, Lowry CA, Rook GA. Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Archives of general psychiatry 2010, 67: 1211–1224.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Yirmiya R, Pollak Y, Morag M, Reichenberg A, Barak O, Avitsur R, et al. Illness, cytokines, and depression. Annals of the New York Academy of Sciences 2000, 917: 478–487.PubMedCrossRefGoogle Scholar
  73. 73.
    Harrison NA, Brydon L, Walker C, Gray MA, Steptoe A, Critchley HD. Inflammation causes mood changes through alterations in subgenual cingulate activity and mesolimbic connectivity. Biological psychiatry 2009, 66: 407–414.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Capuron L, Gumnick JF, Musselman DL, Lawson DH, Reemsnyder A, Nemeroff CB, et al. Neurobehavioral effects of interferon-alpha in cancer patients: phenomenology and paroxetine responsiveness of symptom dimensions. Neuropsychopharmacology: official publication of the American College of Neuropsychopharmacology 2002, 26: 643–652.CrossRefGoogle Scholar
  75. 75.
    Reichenberg A, Yirmiya R, Schuld A, Kraus T, Haack M, Morag A, et al. Cytokine-associated emotional and cognitive disturbances in humans. Archives of general psychiatry 2001, 58: 445–452.PubMedCrossRefGoogle Scholar
  76. 76.
    Abbott R, Whear R, Nikolaou V, Bethel A, Coon JT, Stein K, et al. Tumour necrosis factor-alpha inhibitor therapy in chronic physical illness: A systematic review and meta-analysis of the effect on depression and anxiety. Journal of psychosomatic research 2015, 79: 175–184.PubMedCrossRefGoogle Scholar
  77. 77.
    Kohler O, Benros ME, Nordentoft M, Farkouh ME, Iyengar RL, Mors O, et al. Effect of anti-inflammatory treatment on depression, depressive symptoms, and adverse effects: a systematic review and meta-analysis of randomized clinical trials. JAMA psychiatry 2014, 71: 1381–1391.PubMedCrossRefGoogle Scholar
  78. 78.
    Levine J, Barak Y, Chengappa KN, Rapoport A, Rebey M, Barak V. Cerebrospinal cytokine levels in patients with acute depression. Neuropsychobiology 1999, 40: 171–176.PubMedCrossRefGoogle Scholar
  79. 79.
    Lindqvist D, Janelidze S, Hagell P, Erhardt S, Samuelsson M, Minthon L, et al. Interleukin-6 is elevated in the cerebrospinal fluid of suicide attempters and related to symptom severity. Biol Psychiatry 2009, 66: 287–292.PubMedCrossRefGoogle Scholar
  80. 80.
    Martinez JM, Garakani A, Yehuda R, Gorman JM. Proinflammatory and “resiliency” proteins in the CSF of patients with major depression. Depress Anxiety 2011, 29: 32–38.PubMedCrossRefGoogle Scholar
  81. 81.
    Watson PJ, Andrews PW. Toward a revised evolutionary adaptationist analysis of depression: the social navigation hypothesis. Journal of affective disorders 2002, 72: 1–14.PubMedCrossRefGoogle Scholar
  82. 82.
    Kinney DK, Tanaka M. An evolutionary hypothesis of depression and its symptoms, adaptive value, and risk factors. The Journal of nervous and mental disease 2009, 197: 561–567.PubMedCrossRefGoogle Scholar
  83. 83.
    Raison CL, Miller AH. The evolutionary significance of depression in Pathogen Host Defense (PATHOS-D). Molecular psychiatry 2013, 18: 15–37.PubMedCrossRefGoogle Scholar
  84. 84.
    Cox SS, Speaker KJ, Beninson LA, Craig WC, Paton MM, Fleshner M. Adrenergic and glucocorticoid modulation of the sterile inflammatory response. Brain, behavior, and immunity 2014, 36: 183–192.PubMedCrossRefGoogle Scholar
  85. 85.
    Koo JW, Duman RS. IL-1beta is an essential mediator of the antineurogenic and anhedonic effects of stress. Proc Natl Acad Sci U S A 2008, 105: 751–756.PubMedPubMedCentralCrossRefGoogle Scholar
  86. 86.
    Martinon F, Mayor A, Tschopp J. The inflammasomes: guardians of the body. Annu Rev Immunol 2009, 27: 229–265.PubMedCrossRefGoogle Scholar
  87. 87.
    Fleshner M. Stress-evoked sterile inflammation, danger associated molecular patterns (DAMPs), microbial associated molecular patterns (MAMPs) and the inflammasome. Brain Behav Immun 2012, 27: 1–7.PubMedCrossRefGoogle Scholar
  88. 88.
    Maslanik T, Mahaffey L, Tannura K, Beninson L, Greenwood BN, Fleshner M. The inflammasome and danger associated molecular patterns (DAMPs) are implicated in cytokine and chemokine responses following stressor exposure. Brain Behav Immun 2012, 28: 54–62.PubMedCrossRefGoogle Scholar
  89. 89.
    Iwata M, Ota KT, Duman RS. The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun 2012, 31: 105–114.PubMedPubMedCentralCrossRefGoogle Scholar
  90. 90.
    Pan Y, Chen XY, Zhang QY, Kong LD. Microglial NLRP3 inflammasome activation mediates IL-1beta-related inflammation in prefrontal cortex of depressive rats. Brain Behav Immun 2014, 41: 90–100.PubMedCrossRefGoogle Scholar
  91. 91.
    Wu H, Che X, Tang J, Ma F, Pan K, Zhao M, et al. The K-Cl Cotransporter KCC2 and Chloride Homeostasis: Potential Therapeutic Target in Acute Central Nervous System Injury. Molecular neurobiology 2015.Google Scholar
  92. 92.
    Cohen S, Janicki-Deverts D, Doyle WJ, Miller GE, Frank E, Rabin BS, et al. Chronic stress, glucocorticoid receptor resistance, inflammation, and disease risk. Proc Natl Acad Sci U S A 2012, 109: 5995–5999.PubMedPubMedCentralCrossRefGoogle Scholar
  93. 93.
    Pace TW, Hu F, Miller AH. Cytokine-effects on glucocorticoid receptor function: relevance to glucocorticoid resistance and the pathophysiology and treatment of major depression. Brain, behavior, and immunity 2007, 21: 9–19.PubMedCrossRefGoogle Scholar
  94. 94.
    Paugh SW, Bonten EJ, Savic D, Ramsey LB, Thierfelder WE, Gurung P, et al. NALP3 inflammasome upregulation and CASP1 cleavage of the glucocorticoid receptor cause glucocorticoid resistance in leukemia cells. Nature genetics 2015, 47: 607–614.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Rhen T, Cidlowski JA. Antiinflammatory action of glucocorticoids–new mechanisms for old drugs. The New England journal of medicine 2005, 353: 1711–1723.PubMedCrossRefGoogle Scholar
  96. 96.
    Raison CL, Miller AH. When not enough is too much: the role of insufficient glucocorticoid signaling in the pathophysiology of stress-related disorders. Am J Psychiatry 2003, 160: 1554–1565.PubMedCrossRefGoogle Scholar
  97. 97.
    Alcocer-Gomez E, de Miguel M, Casas-Barquero N, Nunez-Vasco J, Sanchez-Alcazar JA, Fernandez-Rodriguez A, et al. NLRP3 inflammasome is activated in mononuclear blood cells from patients with major depressive disorder. Brain Behav Immun 2014, 36: 111–117.PubMedCrossRefGoogle Scholar
  98. 98.
    Maslanik T, Tannura K, Mahaffey L, Loughridge AB, Beninson L, Ursell L, et al. Commensal bacteria and MAMPs are necessary for stress-induced increases in IL-1beta and IL-18 but not IL-6, IL-10 or MCP-1. PLoS One 2012, 7: e50636.PubMedPubMedCentralCrossRefGoogle Scholar
  99. 99.
    Lyte M, Vulchanova L, Brown DR. Stress at the intestinal surface: catecholamines and mucosa-bacteria interactions. Cell and tissue research 2011, 343: 23–32.PubMedCrossRefGoogle Scholar
  100. 100.
    Parker KH, Beury DW, Ostrand-Rosenberg S. Myeloid-Derived Suppressor Cells: Critical Cells Driving Immune Suppression in the Tumor Microenvironment. Advances in cancer research 2015, 128: 95–139.PubMedPubMedCentralCrossRefGoogle Scholar
  101. 101.
    Li Y, Xiao B, Qiu W, Yang L, Hu B, Tian X, et al. Altered expression of CD4(+)CD25(+) regulatory T cells and its 5-HT(1a) receptor in patients with major depression disorder. Journal of affective disorders 2010, 124: 68–75.PubMedCrossRefGoogle Scholar
  102. 102.
    Zhang Y, Liu L, Peng YL, Liu YZ, Wu TY, Shen XL, et al. Involvement of inflammasome activation in lipopolysaccharide-induced mice depressive-like behaviors. CNS neuroscience & therapeutics 2014, 20: 119–124.CrossRefGoogle Scholar
  103. 103.
    Latz E, Xiao TS, Stutz A. Activation and regulation of the inflammasomes. Nat Rev Immunol 2013, 13: 397–411.PubMedCrossRefGoogle Scholar
  104. 104.
    Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, et al. Autophagy proteins regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by the NALP3 inflammasome. Nat Immunol 2011, 12: 222–230.PubMedCrossRefGoogle Scholar
  105. 105.
    Lamkanfi M, Mueller JL, Vitari AC, Misaghi S, Fedorova A, Deshayes K, et al. Glyburide inhibits the Cryopyrin/Nalp3 inflammasome. The Journal of cell biology 2009, 187: 61–70.PubMedPubMedCentralCrossRefGoogle Scholar
  106. 106.
    Warner-Schmidt JL, Vanover KE, Chen EY, Marshall JJ, Greengard P. Antidepressant effects of selective serotonin reuptake inhibitors (SSRIs) are attenuated by antiinflammatory drugs in mice and humans. Proc Natl Acad Sci U S A 2011, 108: 9262–9267.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Manikowska K, Mikolajczyk M, Mikolajczak PL, Bobkiewicz-Kozlowska T. The influence of mianserin on TNF-alpha, IL-6 and IL-10 serum levels in rats under chronic mild stress. Pharmacol Rep 2014, 66: 22–27.PubMedCrossRefGoogle Scholar
  108. 108.
    Alboni S, Benatti C, Montanari C, Tascedda F, Brunello N. Chronic antidepressant treatments resulted in altered expression of genes involved in inflammation in the rat hypothalamus. European journal of pharmacology 2013, 721: 158–167.PubMedCrossRefGoogle Scholar
  109. 109.
    Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004, 4: 499–511.PubMedCrossRefGoogle Scholar
  110. 110.
    Liu J, Buisman-Pijlman F, Hutchinson MR. Toll-like receptor 4: innate immune regulator of neuroimmune and neuroendocrine interactions in stress and major depressive disorder. Frontiers in neuroscience 2014, 8: 309.PubMedPubMedCentralGoogle Scholar
  111. 111.
    Bianchi ME. DAMPs, PAMPs and alarmins: all we need to know about danger. Journal of leukocyte biology 2007, 81: 1–5.PubMedCrossRefGoogle Scholar
  112. 112.
    Belvin MP, Anderson KV. A conserved signaling pathway: the Drosophila toll-dorsal pathway. Annual review of cell and developmental biology 1996, 12: 393–416.PubMedCrossRefGoogle Scholar
  113. 113.
    Medzhitov R, Preston-Hurlburt P, Janeway CA, Jr. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature 1997, 388: 394–397.PubMedCrossRefGoogle Scholar
  114. 114.
    Kawai T, Akira S. TLR signaling. Seminars in immunology 2007, 19: 24–32.PubMedCrossRefGoogle Scholar
  115. 115.
    Tobias PS, Soldau K, Ulevitch RJ. Isolation of a lipopolysaccharide-binding acute phase reactant from rabbit serum. The Journal of experimental medicine 1986, 164: 777–793.PubMedCrossRefGoogle Scholar
  116. 116.
    Kawai T, Akira S. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat Immunol 2010, 11: 373–384.PubMedCrossRefGoogle Scholar
  117. 117.
    Oliveira J, Etain B, Lajnef M, Hamdani N, Bennabi M, Bengoufa D, et al. Combined effect of TLR2 gene polymorphism and early life stress on the age at onset of bipolar disorders. PloS one 2015, 10: e0119702.PubMedPubMedCentralCrossRefGoogle Scholar
  118. 118.
    Wu MK, Huang TL, Huang KW, Huang YL, Hung YY. Association between toll-like receptor 4 expression and symptoms of major depressive disorder. Neuropsychiatric disease and treatment 2015, 11: 1853–1857.PubMedPubMedCentralGoogle Scholar
  119. 119.
    Mohn CE, Fernandez-Solari J, De Laurentiis A, Bornstein SR, Ehrhart-Bornstein M, Rettori V. Adrenal gland responses to lipopolysaccharide after stress and ethanol administration in male rats. Stress 2011, 14: 216–226.PubMedCrossRefGoogle Scholar
  120. 120.
    Kanczkowski W, Alexaki VI, Tran N, Grossklaus S, Zacharowski K, Martinez A, et al. Hypothalamo-pituitary and immune-dependent adrenal regulation during systemic inflammation. Proc Natl Acad Sci U S A 2013, 110: 14801–14806.PubMedPubMedCentralCrossRefGoogle Scholar
  121. 121.
    Vakharia K, Hinson JP. Lipopolysaccharide directly stimulates cortisol secretion by human adrenal cells by a cyclooxygenase-dependent mechanism. Endocrinology 2005, 146: 1398–1402.PubMedCrossRefGoogle Scholar
  122. 122.
    Loum-Ribot E, Lafon P, Chaigniau M, Tramu G, Corio M. Glucocorticoids down-regulate lipopolysaccharide-induced de novo production of neurotensin mRNA in the rat hypothalamic, paraventricular, corticotrophin-releasing hormone neurons. Neuroimmunomodulation 2006, 13: 170–178.PubMedCrossRefGoogle Scholar
  123. 123.
    Goebel M, Stengel A, Wang L, Reeve J, Jr., Tache Y. Lipopolysaccharide increases plasma levels of corticotropin-releasing hormone in rats. Neuroendocrinology 2011, 93: 165–173.PubMedCrossRefGoogle Scholar
  124. 124.
    Elenkov IJ, Kovacs K, Kiss J, Bertok L, Vizi ES. Lipopolysaccharide is able to bypass corticotrophin-releasing factor in affecting plasma ACTH and corticosterone levels: evidence from rats with lesions of the paraventricular nucleus. J Endocrinol 1992, 133: 231–236.PubMedCrossRefGoogle Scholar
  125. 125.
    Van Bogaert T, De Bosscher K, Libert C. Crosstalk between TNF and glucocorticoid receptor signaling pathways. Cytokine Growth Factor Rev 2010, 21: 275–286.PubMedCrossRefGoogle Scholar
  126. 126.
    Mouihate A, Galic MA, Ellis SL, Spencer SJ, Tsutsui S, Pittman QJ. Early life activation of toll-like receptor 4 reprograms neural anti-inflammatory pathways. The Journal of neuroscience: the official journal of the Society for Neuroscience 2010, 30: 7975–7983.CrossRefGoogle Scholar
  127. 127.
    Sominsky L, Fuller EA, Bondarenko E, Ong LK, Averell L, Nalivaiko E, et al. Functional programming of the autonomic nervous system by early life immune exposure: implications for anxiety. PloS one 2013, 8: e57700.PubMedPubMedCentralCrossRefGoogle Scholar
  128. 128.
    Yamaguchi N, Ogawa S, Okada S. Cyclooxygenase and nitric oxide synthase in the presympathetic neurons in the paraventricular hypothalamic nucleus are involved in restraint stress-induced sympathetic activation in rats. Neuroscience 2010, 170: 773–781.PubMedCrossRefGoogle Scholar
  129. 129.
    Ma Y, Matsuwaki T, Yamanouchi K, Nishihara M. Cyclooxygenase-2-related signaling in the hypothalamus plays differential roles in response to various acute stresses. Brain Res 2013, 1508: 23–33.PubMedCrossRefGoogle Scholar
  130. 130.
    Hines DJ, Choi HB, Hines RM, Phillips AG, MacVicar BA. Prevention of LPS-induced microglia activation, cytokine production and sickness behavior with TLR4 receptor interfering peptides. PloS one 2013, 8: e60388.PubMedPubMedCentralCrossRefGoogle Scholar
  131. 131.
    Keri S, Szabo C, Kelemen O. Expression of Toll-Like Receptors in peripheral blood mononuclear cells and response to cognitive-behavioral therapy in major depressive disorder. Brain Behav Immun 2014, 40: 235–243.PubMedCrossRefGoogle Scholar
  132. 132.
    Watters TM, Kenny EF, O’Neill LA. Structure, function and regulation of the Toll/IL-1 receptor adaptor proteins. Immunology and cell biology 2007, 85: 411–419.PubMedCrossRefGoogle Scholar
  133. 133.
    Xu Y, Tao X, Shen B, Horng T, Medzhitov R, Manley JL, et al. Structural basis for signal transduction by the Toll/interleukin-1 receptor domains. Nature 2000, 408: 111–115.PubMedCrossRefGoogle Scholar
  134. 134.
    Zhao M, Zhou A, Xu L, Zhang X. The role of TLR4-mediated PTEN/PI3K/AKT/NF-kappaB signaling pathway in neuroinflammation in hippocampal neurons. Neuroscience 2014, 269: 93–101.PubMedCrossRefGoogle Scholar
  135. 135.
    Lewis SS, Loram LC, Hutchinson MR, Li CM, Zhang Y, Maier SF, et al. (+)-naloxone, an opioid-inactive toll-like receptor 4 signaling inhibitor, reverses multiple models of chronic neuropathic pain in rats. The journal of pain: official journal of the American Pain Society 2012, 13: 498–506.CrossRefGoogle Scholar
  136. 136.
    Heneka MT, Kummer MP, Latz E. Innate immune activation in neurodegenerative disease. Nat Rev Immunol 2014, 14: 463–477.PubMedCrossRefGoogle Scholar
  137. 137.
    Olah M, Biber K, Vinet J, Boddeke HW. Microglia phenotype diversity. CNS & neurological disorders drug targets 2011, 10: 108–118.CrossRefGoogle Scholar
  138. 138.
    Ajmone-Cat MA, Mancini M, De Simone R, Cilli P, Minghetti L. Microglial polarization and plasticity: evidence from organotypic hippocampal slice cultures. Glia 2013, 61: 1698–1711.PubMedCrossRefGoogle Scholar
  139. 139.
    Harms AS, Cao S, Rowse AL, Thome AD, Li X, Mangieri LR, et al. MHCII is required for alpha-synuclein-induced activation of microglia, CD4 T cell proliferation, and dopaminergic neurodegeneration. The Journal of neuroscience: the official journal of the Society for Neuroscience 2013, 33: 9592–9600.CrossRefGoogle Scholar
  140. 140.
    Kreisel T, Frank MG, Licht T, Reshef R, Ben-Menachem-Zidon O, Baratta MV, et al. Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry 2014, 19: 699–709.PubMedCrossRefGoogle Scholar
  141. 141.
    Horikawa H, Kato TA, Mizoguchi Y, Monji A, Seki Y, Ohkuri T, et al. Inhibitory effects of SSRIs on IFN-gamma induced microglial activation through the regulation of intracellular calcium. Prog Neuropsychopharmacol Biol Psychiatry 2010, 34: 1306–1316.PubMedCrossRefGoogle Scholar
  142. 142.
    Obuchowicz E, Bielecka AM, Paul-Samojedny M, Pudelko A, Kowalski J. Imipramine and fluoxetine inhibit LPS-induced activation and affect morphology of microglial cells in the rat glial culture. Pharmacol Rep 2014, 66: 34–43.PubMedCrossRefGoogle Scholar
  143. 143.
    Dhami KS, Churchward MA, Baker GB, Todd KG. Fluoxetine and citalopram decrease microglial release of glutamate and D-serine to promote cortical neuronal viability following ischemic insult. Molecular and cellular neurosciences 2013, 56: 365–374.PubMedCrossRefGoogle Scholar
  144. 144.
    Zhang F, Zhou H, Wilson BC, Shi JS, Hong JS, Gao HM. Fluoxetine protects neurons against microglial activation-mediated neurotoxicity. Parkinsonism & related disorders 2012, 18 Suppl 1: S213–S217.CrossRefGoogle Scholar
  145. 145.
    Chung YC, Kim SR, Park JY, Chung ES, Park KW, Won SY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2011, 60: 963–974.PubMedCrossRefGoogle Scholar
  146. 146.
    Fest S, Aldo PB, Abrahams VM, Visintin I, Alvero A, Chen R, et al. Trophoblast-macrophage interactions: a regulatory network for the protection of pregnancy. Am J Reprod Immunol 2007, 57: 55–66.PubMedCrossRefGoogle Scholar
  147. 147.
    Houser BL. Decidual macrophages and their roles at the maternal-fetal interface. Yale J Biol Med 2012, 85: 105–118.PubMedPubMedCentralGoogle Scholar
  148. 148.
    Makrigiannakis A, Minas V, Kalantaridou SN, Nikas G, Chrousos GP. Hormonal and cytokine regulation of early implantation. Trends in endocrinology and metabolism: TEM 2006, 17: 178–185.PubMedCrossRefGoogle Scholar
  149. 149.
    Hanna J, Goldman-Wohl D, Hamani Y, Avraham I, Greenfield C, Natanson-Yaron S, et al. Decidual NK cells regulate key developmental processes at the human fetal-maternal interface. Nat Med 2006, 12: 1065–1074.PubMedCrossRefGoogle Scholar
  150. 150.
    Manaster I, Mandelboim O. The unique properties of uterine NK cells. Am J Reprod Immunol 2010, 63: 434–444.PubMedCrossRefGoogle Scholar
  151. 151.
    Evans J, Catalano RD, Brown P, Sherwin R, Critchley HO, Fazleabas AT, et al. Prokineticin 1 mediates fetal-maternal dialogue regulating endometrial leukemia inhibitory factor. FASEB journal: official publication of the Federation of American Societies for Experimental Biology 2009, 23: 2165–2175.CrossRefGoogle Scholar
  152. 152.
    Marwood M, Visser K, Salamonsen LA, Dimitriadis E. Interleukin-11 and leukemia inhibitory factor regulate the adhesion of endometrial epithelial cells: implications in fertility regulation. Endocrinology 2009, 150: 2915–2923.PubMedCrossRefGoogle Scholar
  153. 153.
    Jones RL, Hannan NJ, Kaitu’u TJ, Zhang J, Salamonsen LA. Identification of chemokines important for leukocyte recruitment to the human endometrium at the times of embryo implantation and menstruation. J Clin Endocrinol Metab 2004, 89: 6155–6167.PubMedCrossRefGoogle Scholar
  154. 154.
    Barkai U, Kraicer PF. Intrauterine signaling and embryonic implantation. Biol Signals 1996, 5: 111–121.PubMedCrossRefGoogle Scholar
  155. 155.
    Maekawa F, Yamanouchi K. Effect of deprivation of serotonin by p-chlorophenylalanine on induction and maintenance of pseudopregnancy in female rats. Brain Res Bull 1996, 39: 317–321.PubMedCrossRefGoogle Scholar
  156. 156.
    Mitchell JA, Hammer RE, Goldman H. Serotonin-induced disruption of implantation in the rat: II. Suppression of decidualization. Biol Reprod 1983, 29: 151–156.PubMedCrossRefGoogle Scholar
  157. 157.
    Gelman PL, Flores-Ramos M, Lopez-Martinez M, Fuentes CC, Grajeda JP. Hypothalamic-pituitary-adrenal axis function during perinatal depression. Neuroscience bulletin 2015, 31: 338–350.PubMedCrossRefGoogle Scholar
  158. 158.
    Figueiredo AS, Schumacher A. The Th17/Treg paradigm in pregnancy. Immunology 2016.Google Scholar
  159. 159.
    Trowsdale J, Betz AG. Mother’s little helpers: mechanisms of maternal-fetal tolerance. Nat Immunol 2006, 7: 241–246.PubMedCrossRefGoogle Scholar
  160. 160.
    Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996, 17: 138–146.PubMedCrossRefGoogle Scholar
  161. 161.
    Huber SA, Kupperman J, Newell MK. Estradiol prevents and testosterone promotes Fas-dependent apoptosis in CD4+ Th2 cells by altering Bcl 2 expression. Lupus 1999, 8: 384–387.PubMedCrossRefGoogle Scholar
  162. 162.
    Xue L, Gyles SL, Wettey FR, Gazi L, Townsend E, Hunter MG, et al. Prostaglandin D2 causes preferential induction of proinflammatory Th2 cytokine production through an action on chemoattractant receptor-like molecule expressed on Th2 cells. J Immunol 2005, 175: 6531–6536.PubMedCrossRefGoogle Scholar
  163. 163.
    Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989, 7: 145–173.PubMedCrossRefGoogle Scholar
  164. 164.
    Sykes L, MacIntyre DA, Yap XJ, Teoh TG, Bennett PR. The Th1:th2 dichotomy of pregnancy and preterm labour. Mediators Inflamm 2012, 2012: 967629.PubMedPubMedCentralGoogle Scholar
  165. 165.
    Saito S, Nakashima A, Shima T, Ito M. Th1/Th2/Th17 and regulatory T-cell paradigm in pregnancy. Am J Reprod Immunol 2010, 63: 601–610.PubMedCrossRefGoogle Scholar
  166. 166.
    Piccinni MP. T cells in normal pregnancy and recurrent pregnancy loss. Reprod Biomed Online 2007, 14 Spec No 1: 95–99.Google Scholar
  167. 167.
    Dealtry GB, Clark DE, Sharkey A, Charnock-Jones DS, Smith SK. Expression and localization of the Th2-type cytokine interleukin-13 and its receptor in the placenta during human pregnancy. Am J Reprod Immunol 1998, 40: 283–290.PubMedCrossRefGoogle Scholar
  168. 168.
    Roth I, Corry DB, Locksley RM, Abrams JS, Litton MJ, Fisher SJ. Human placental cytotrophoblasts produce the immunosuppressive cytokine interleukin 10. J Exp Med 1996, 184: 539–548.PubMedCrossRefGoogle Scholar
  169. 169.
    Bennett WA, Lagoo-Deenadayalan S, Brackin MN, Hale E, Cowan BD. Cytokine expression by models of human trophoblast as assessed by a semiquantitative reverse transcription-polymerase chain reaction technique. Am J Reprod Immunol 1996, 36: 285–294.PubMedCrossRefGoogle Scholar
  170. 170.
    Liu F, Guo J, Tian T, Wang H, Dong F, Huang H, et al. Placental trophoblasts shifted Th1/Th2 balance toward Th2 and inhibited Th17 immunity at fetomaternal interface. APMIS 2011, 119: 597–604.PubMedCrossRefGoogle Scholar
  171. 171.
    Makhseed M, Raghupathy R, Azizieh F, Al-Azemi MM, Hassan NA, Bandar A. Mitogen-induced cytokine responses of maternal peripheral blood lymphocytes indicate a differential Th-type bias in normal pregnancy and pregnancy failure. Am J Reprod Immunol 1999, 42: 273–281.PubMedCrossRefGoogle Scholar
  172. 172.
    Piccinni MP. T cell tolerance towards the fetal allograft. J Reprod Immunol 2010, 85: 71–75.PubMedCrossRefGoogle Scholar
  173. 173.
    Fortunato SJ, Menon R, Lombardi SJ. Interleukin-10 and transforming growth factor-beta inhibit amniochorion tumor necrosis factor-alpha production by contrasting mechanisms of action: therapeutic implications in prematurity. Am J Obstet Gynecol 1997, 177: 803–809.PubMedCrossRefGoogle Scholar
  174. 174.
    Michimata T, Tsuda H, Sakai M, Fujimura M, Nagata K, Nakamura M, et al. Accumulation of CRTH2-positive T-helper 2 and T-cytotoxic 2 cells at implantation sites of human decidua in a prostaglandin D(2)-mediated manner. Mol Hum Reprod 2002, 8: 181–187.PubMedCrossRefGoogle Scholar
  175. 175.
    Michimata T, Sakai M, Miyazaki S, Ogasawara MS, Suzumori K, Aoki K, et al. Decrease of T-helper 2 and T-cytotoxic 2 cells at implantation sites occurs in unexplained recurrent spontaneous abortion with normal chromosomal content. Hum Reprod 2003, 18: 1523–1528.PubMedCrossRefGoogle Scholar
  176. 176.
    Piccinni MP, Beloni L, Livi C, Maggi E, Scarselli G, Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat Med 1998, 4: 1020–1024.PubMedCrossRefGoogle Scholar
  177. 177.
    Szekeres-Bartho J, Wegmann TG. A progesterone-dependent immunomodulatory protein alters the Th1/Th2 balance. J Reprod Immunol 1996, 31: 81–95.PubMedCrossRefGoogle Scholar
  178. 178.
    Dekel N, Gnainsky Y, Granot I, Mor G. Inflammation and implantation. Am J Reprod Immunol 2010, 63: 17–21.PubMedPubMedCentralCrossRefGoogle Scholar
  179. 179.
    Wegmann TG, Lin H, Guilbert L, Mosmann TR. Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon? Immunol Today 1993, 14: 353–356.PubMedCrossRefGoogle Scholar
  180. 180.
    McCracken SA, Gallery E, Morris JM. Pregnancy-specific down-regulation of NF-kappa B expression in T cells in humans is essential for the maintenance of the cytokine profile required for pregnancy success. J Immunol 2004, 172: 4583–4591.PubMedCrossRefGoogle Scholar
  181. 181.
    Mor G, Cardenas I. The immune system in pregnancy: a unique complexity. Am J Reprod Immunol 2010, 63: 425–433.PubMedPubMedCentralCrossRefGoogle Scholar
  182. 182.
    Piccinni MP, Romagnani S. Regulation of fetal allograft survival by a hormone-controlled Th1- and Th2-type cytokines. Immunol Res 1996, 15: 141–150.PubMedCrossRefGoogle Scholar
  183. 183.
    Matsuoka T, Matsubara T, Katayama K, Takeda K, Koga M, Furukawa S. Increase of cord blood cytokine-producing T cells in intrauterine infection. Pediatrics international: official journal of the Japan Pediatric Society 2001, 43: 453–457.CrossRefGoogle Scholar
  184. 184.
    Goldberg MR, Nadiv O, Luknar-Gabor N, Zadik-Mnuhin G, Tovbin J, Katz Y. Correlation of Th1-type cytokine expression and induced proliferation to lipopolysaccharide. American journal of respiratory cell and molecular biology 2008, 38: 733–737.PubMedCrossRefGoogle Scholar
  185. 185.
    Goldenberg RL, Andrews WW, Hauth JC. Choriodecidual infection and preterm birth. Nutrition reviews 2002, 60: S19–S25.PubMedCrossRefGoogle Scholar
  186. 186.
    Hollier LM, Rivera MK, Henninger E, Gilstrap LC, 3rd, Marshall GD, Jr. T helper cell cytokine profiles in preterm labor. Am J Reprod Immunol 2004, 52: 192–196.PubMedCrossRefGoogle Scholar
  187. 187.
    Meltzer-Brody S. New insights into perinatal depression: pathogenesis and treatment during pregnancy and postpartum. Dialogues Clin Neurosci 2011, 13: 89–100.PubMedPubMedCentralGoogle Scholar
  188. 188.
    Mor G, Cardenas I, Abrahams V, Guller S. Inflammation and pregnancy: the role of the immune system at the implantation site. Ann N Y Acad Sci 2011, 1221: 80–87.PubMedPubMedCentralCrossRefGoogle Scholar
  189. 189.
    Romero R, Espinoza J, Goncalves LF, Kusanovic JP, Friel LA, Nien JK. Inflammation in preterm and term labour and delivery. Semin Fetal Neonatal Med 2006, 11: 317–326.PubMedCrossRefGoogle Scholar
  190. 190.
    Mastorakos G, Ilias I. Maternal and fetal hypothalamic-pituitary-adrenal axes during pregnancy and postpartum. Ann N Y Acad Sci 2003, 997: 136–149.PubMedCrossRefGoogle Scholar
  191. 191.
    Koga K, Izumi G, Mor G, Fujii T, Osuga Y. Toll-like receptors at the maternal-fetal interface in normal pregnancy and pregnancy complications. Am J Reprod Immunol 2014, 72: 192–205.PubMedCrossRefGoogle Scholar
  192. 192.
    Mor G, Romero R, Aldo PB, Abrahams VM. Is the trophoblast an immune regulator? The role of Toll-like receptors during pregnancy. Critical reviews in immunology 2005, 25: 375–388.PubMedCrossRefGoogle Scholar
  193. 193.
    Mor G. Inflammation and pregnancy: the role of toll-like receptors in trophoblast-immune interaction. Ann N Y Acad Sci 2008, 1127: 121–128.PubMedCrossRefGoogle Scholar
  194. 194.
    Klaffenbach D, Rascher W, Rollinghoff M, Dotsch J, Meissner U, Schnare M. Regulation and signal transduction of toll-like receptors in human chorioncarcinoma cell lines. Am J Reprod Immunol 2005, 53: 77–84.PubMedCrossRefGoogle Scholar
  195. 195.
    Beijar EC, Mallard C, Powell TL. Expression and subcellular localization of TLR-4 in term and first trimester human placenta. Placenta 2006, 27: 322–326.PubMedCrossRefGoogle Scholar
  196. 196.
    Kumazaki K, Nakayama M, Yanagihara I, Suehara N, Wada Y. Immunohistochemical distribution of Toll-like receptor 4 in term and preterm human placentas from normal and complicated pregnancy including chorioamnionitis. Human pathology 2004, 35: 47–54.PubMedCrossRefGoogle Scholar
  197. 197.
    Mitsunari M, Yoshida S, Shoji T, Tsukihara S, Iwabe T, Harada T, et al. Macrophage-activating lipopeptide-2 induces cyclooxygenase-2 and prostaglandin E(2) via toll-like receptor 2 in human placental trophoblast cells. J Reprod Immunol 2006, 72: 46–59.PubMedCrossRefGoogle Scholar
  198. 198.
    Abrahams VM, Bole-Aldo P, Kim YM, Straszewski-Chavez SL, Chaiworapongsa T, Romero R, et al. Divergent trophoblast responses to bacterial products mediated by TLRs. J Immunol 2004, 173: 4286–4296.PubMedCrossRefGoogle Scholar
  199. 199.
    Canavan TP, Simhan HN. Innate immune function of the human decidual cell at the maternal-fetal interface. J Reprod Immunol 2007, 74: 46–52.PubMedCrossRefGoogle Scholar
  200. 200.
    Dulay AT, Buhimschi CS, Zhao G, Oliver EA, Mbele A, Jing S, et al. Soluble TLR2 is present in human amniotic fluid and modulates the intraamniotic inflammatory response to infection. J Immunol 2009, 182: 7244–7253.PubMedCrossRefGoogle Scholar
  201. 201.
    Bull SJ, Huezo-Diaz P, Binder EB, Cubells JF, Ranjith G, Maddock C, et al. Functional polymorphisms in the interleukin-6 and serotonin transporter genes, and depression and fatigue induced by interferon-alpha and ribavirin treatment. Mol Psychiatry 2009, 14: 1095–1104.PubMedCrossRefGoogle Scholar
  202. 202.
    Capuron L, Miller AH. Cytokines and psychopathology: lessons from interferon-alpha. Biol Psychiatry 2004, 56: 819–824.PubMedCrossRefGoogle Scholar
  203. 203.
    Lotrich FE, Rabinovitz M, Gironda P, Pollock BG. Depression following pegylated interferon-alpha: characteristics and vulnerability. J Psychosom Res 2007, 63: 131–135.PubMedPubMedCentralCrossRefGoogle Scholar
  204. 204.
    Maddock C, Landau S, Barry K, Maulayah P, Hotopf M, Cleare AJ, et al. Psychopathological symptoms during interferon-alpha and ribavirin treatment: effects on virologic response. Mol Psychiatry 2005, 10: 332–333.PubMedCrossRefGoogle Scholar
  205. 205.
    Osborne LM, Monk C. Perinatal depression–the fourth inflammatory morbidity of pregnancy?: Theory and literature review. Psychoneuroendocrinology 2013, 38: 1929–1952.PubMedPubMedCentralCrossRefGoogle Scholar
  206. 206.
    Anisman H. Cascading effects of stressors and inflammatory immune system activation: implications for major depressive disorder. J Psychiatry Neurosci 2009, 34: 4–20.PubMedPubMedCentralGoogle Scholar
  207. 207.
    Maes M. Inflammatory and oxidative and nitrosative stress pathways underpinning chronic fatigue, somatization and psychosomatic symptoms. Curr Opin Psychiatry 2009, 22: 75–83.PubMedCrossRefGoogle Scholar
  208. 208.
    Maes M, Yirmyia R, Noraberg J, Brene S, Hibbeln J, Perini G, et al. The inflammatory & neurodegenerative (I&ND) hypothesis of depression: leads for future research and new drug developments in depression. Metab Brain Dis 2009, 24: 27–53.PubMedCrossRefGoogle Scholar
  209. 209.
    Gadek-Michalska A, Bugajski J. Interleukin-1 (IL-1) in stress-induced activation of limbic-hypothalamic-pituitary adrenal axis. Pharmacol Rep 2011, 62: 969–982.CrossRefGoogle Scholar
  210. 210.
    Hannibal J, Jessop DS, Fahrenkrug J, Harbuz MS, Larsen PJ. PACAP gene expression in neurons of the rat hypothalamo-pituitary-adrenocortical axis is induced by endotoxin and interleukin-1beta. Neuroendocrinology 1999, 70: 73–82.PubMedCrossRefGoogle Scholar
  211. 211.
    Joels M, Baram TZ. The neuro-symphony of stress. Nat Rev Neurosci 2009, 10: 459–466.PubMedPubMedCentralGoogle Scholar
  212. 212.
    John CD, Buckingham JC. Cytokines: regulation of the hypothalamo-pituitary-adrenocortical axis. Curr Opin Pharmacol 2003, 3: 78–84.PubMedCrossRefGoogle Scholar
  213. 213.
    Ferri CC, Ferguson AV. Interleukin-1 beta depolarizes paraventricular nucleus parvocellular neurones. J Neuroendocrinol 2003, 15: 126–133.PubMedCrossRefGoogle Scholar
  214. 214.
    Chover-Gonzalez AJ, Harbuz MS, Lightman SL. Effect of adrenalectomy and stress on interleukin-1 beta-mediated activation of hypothalamic corticotropin-releasing factor mRNA. J Neuroimmunol 1993, 42: 155–160.PubMedCrossRefGoogle Scholar
  215. 215.
    Mehet DK, Philip J, Solito E, Buckingham JC, John CD. Evidence from in vitro and in vivo studies showing that nuclear factor-kappaB within the pituitary folliculostellate cells and corticotrophs regulates adrenocorticotrophic hormone secretion in experimental endotoxaemia. J Neuroendocrinol 2012, 24: 862–873.PubMedCrossRefGoogle Scholar
  216. 216.
    Wang X, Wu H, Miller AH. Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function. Molecular psychiatry 2004, 9: 65–75.PubMedCrossRefGoogle Scholar
  217. 217.
    Hu F, Pace TW, Miller AH. Interferon-alpha inhibits glucocorticoid receptor-mediated gene transcription via STAT5 activation in mouse HT22 cells. Brain, behavior, and immunity 2009, 23: 455–463.PubMedPubMedCentralCrossRefGoogle Scholar
  218. 218.
    Van Bogaert T, Vandevyver S, Dejager L, Van Hauwermeiren F, Pinheiro I, Petta I, et al. Tumor necrosis factor inhibits glucocorticoid receptor function in mice: a strong signal toward lethal shock. The Journal of biological chemistry 2011, 286: 26555–26567.PubMedPubMedCentralCrossRefGoogle Scholar
  219. 219.
    Busillo JM, Cidlowski JA. The five Rs of glucocorticoid action during inflammation: ready, reinforce, repress, resolve, and restore. Trends in endocrinology and metabolism: TEM 2013, 24: 109–119.PubMedPubMedCentralCrossRefGoogle Scholar
  220. 220.
    Langlais D, Couture C, Balsalobre A, Drouin J. Regulatory network analyses reveal genome-wide potentiation of LIF signaling by glucocorticoids and define an innate cell defense response. PLoS genetics 2008, 4: e1000224.PubMedPubMedCentralCrossRefGoogle Scholar
  221. 221.
    Jo WK, Zhang Y, Emrich HM, Dietrich DE. Glia in the cytokine-mediated onset of depression: fine tuning the immune response. Frontiers in cellular neuroscience 2015, 9: 268.PubMedPubMedCentralCrossRefGoogle Scholar
  222. 222.
    Bay-Richter C, Linderholm KR, Lim CK, Samuelsson M, Traskman-Bendz L, Guillemin GJ, et al. A role for inflammatory metabolites as modulators of the glutamate N-methyl-D-aspartate receptor in depression and suicidality. Brain, behavior, and immunity 2015, 43: 110–117.PubMedCrossRefGoogle Scholar
  223. 223.
    Cai W, Khaoustov VI, Xie Q, Pan T, Le W, Yoffe B. Interferon-alpha-induced modulation of glucocorticoid and serotonin receptors as a mechanism of depression. J Hepatol 2005, 42: 880–887.PubMedCrossRefGoogle Scholar
  224. 224.
    Dunn AJ. Effects of cytokines and infections on brain neurochemistry. Clin Neurosci Res 2006, 6: 52–68.PubMedPubMedCentralCrossRefGoogle Scholar
  225. 225.
    Dunn AJ, Wang J, Ando T. Effects of cytokines on cerebral neurotransmission. Comparison with the effects of stress. Adv Exp Med Biol 1999, 461: 117–127.PubMedCrossRefGoogle Scholar
  226. 226.
    Raison CL, Capuron L, Miller AH. Cytokines sing the blues: inflammation and the pathogenesis of depression. Trends Immunol 2006, 27: 24–31.PubMedCrossRefGoogle Scholar
  227. 227.
    Fang J, Han D, Hong J, Tan Q, Tian Y. The chemokine, macrophage inflammatory protein-2gamma, reduces the expression of glutamate transporter-1 on astrocytes and increases neuronal sensitivity to glutamate excitotoxicity. Journal of neuroinflammation 2012, 9: 267.PubMedPubMedCentralCrossRefGoogle Scholar
  228. 228.
    Persson M, Pekna M, Hansson E, Ronnback L. The complement-derived anaphylatoxin C5a increases microglial GLT-1 expression and glutamate uptake in a TNF-alpha-independent manner. Eur J Neurosci 2009, 29: 267–274.PubMedCrossRefGoogle Scholar
  229. 229.
    Tilleux S, Hermans E. Down-regulation of astrocytic GLAST by microglia-related inflammation is abrogated in dibutyryl cAMP-differentiated cultures. J Neurochem 2008, 105: 2224–2236.PubMedCrossRefGoogle Scholar
  230. 230.
    Haroon E, Raison CL, Miller AH. Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology 2011, 37: 137–162.PubMedPubMedCentralCrossRefGoogle Scholar
  231. 231.
    Zhu CB, Carneiro AM, Dostmann WR, Hewlett WA, Blakely RD. p38 MAPK activation elevates serotonin transport activity via a trafficking-independent, protein phosphatase 2A-dependent process. J Biol Chem 2005, 280: 15649–15658.PubMedCrossRefGoogle Scholar
  232. 232.
    Zhu CB, Lindler KM, Owens AW, Daws LC, Blakely RD, Hewlett WA. Interleukin-1 receptor activation by systemic lipopolysaccharide induces behavioral despair linked to MAPK regulation of CNS serotonin transporters. Neuropsychopharmacology 2010, 35: 2510–2520.PubMedPubMedCentralCrossRefGoogle Scholar
  233. 233.
    Kekuda R, Leibach FH, Furesz TC, Smith CH, Ganapathy V. Polarized distribution of interleukin-1 receptors and their role in regulation of serotonin transporter in placenta. J Pharmacol Exp Ther 2000, 292: 1032–1041.PubMedGoogle Scholar
  234. 234.
    Busse M, Busse S, Myint AM, Gos T, Dobrowolny H, Muller UJ, et al. Decreased quinolinic acid in the hippocampus of depressive patients: evidence for local anti-inflammatory and neuroprotective responses? European archives of psychiatry and clinical neuroscience 2015, 265: 321–329.PubMedCrossRefGoogle Scholar
  235. 235.
    Steiner J, Bielau H, Brisch R, Danos P, Ullrich O, Mawrin C, et al. Immunological aspects in the neurobiology of suicide: elevated microglial density in schizophrenia and depression is associated with suicide. Journal of psychiatric research 2008, 42: 151–157.PubMedCrossRefGoogle Scholar
  236. 236.
    Kudo Y. The role of placental indoleamine 2,3-dioxygenase in human pregnancy. Obstetrics & gynecology science 2013, 56: 209–216.CrossRefGoogle Scholar
  237. 237.
    Munn DH, Shafizadeh E, Attwood JT, Bondarev I, Pashine A, Mellor AL. Inhibition of T cell proliferation by macrophage tryptophan catabolism. The Journal of experimental medicine 1999, 189: 1363–1372.PubMedPubMedCentralCrossRefGoogle Scholar
  238. 238.
    Sacks GP, Studena K, Sargent K, Redman CW. Normal pregnancy and preeclampsia both produce inflammatory changes in peripheral blood leukocytes akin to those of sepsis. Am J Obstet Gynecol 1998, 179: 80–86.PubMedCrossRefGoogle Scholar
  239. 239.
    Howard LM, Molyneaux E, Dennis CL, Rochat T, Stein A, Milgrom J. Non-psychotic mental disorders in the perinatal period. Lancet 2014, 384: 1775–1788.PubMedCrossRefGoogle Scholar
  240. 240.
    Feng J, Fan G. The role of DNA methylation in the central nervous system and neuropsychiatric disorders. International review of neurobiology 2009, 89: 67–84.PubMedCrossRefGoogle Scholar
  241. 241.
    Sun H, Kennedy PJ, Nestler EJ. Epigenetics of the depressed brain: role of histone acetylation and methylation. Neuropsychopharmacology 2013, 38: 124–137.PubMedCrossRefGoogle Scholar

Copyright information

© Shanghai Institutes for Biological Sciences, CAS and Springer Science+Business Media Singapore 2016

Authors and Affiliations

  • Philippe Leff-Gelman
    • 1
  • Ismael Mancilla-Herrera
    • 1
  • Mónica Flores-Ramos
    • 2
    • 5
  • Carlos Cruz-Fuentes
    • 2
  • Juan Pablo Reyes-Grajeda
    • 3
  • María del Pilar García-Cuétara
    • 4
  • Marielle Danitza Bugnot-Pérez
    • 4
  • David Ellioth Pulido-Ascencio
    • 1
  1. 1.National Institute of PerinatologyMexico CityMexico
  2. 2.National Institute of PsychiatryMexico CityMexico
  3. 3.National Institute of Genomic MedicineMexico CityMexico
  4. 4.Faculty of PsychologyAnahuac UniversityHuixquilucanMexico
  5. 5.National Council of Science and TechnologyMexico CityMexico

Personalised recommendations